Search Results

Your search for Javier Cort��s, MD,Javier Cort��s, MD matches 2 pages

Showing 1 - 2

By Matthew Stenger / Monday, January 11, 2016 9:30 AM

No Benefit Shown With Afatinib in HER2-Positive Breast Cancer With Progressive Brain Metastases

In the phase II LUX-Breast 3 trial reported in The Lancet Oncology, Cortés et al found that afatinib (Gilotrif) alone or combined with vinorelbine did not increase patient benefit vs investigator choice of treatment in patients with HER2-positive breast cancer and progressive brain...

breast cancer

By Caroline Helwick / Monday, September 29, 2014 11:38 AM

ESMO 2014: CLEOPATRA Study Shows ‘Unprecedented’ Survival With Dual HER2 Blockade in Metastatic Breast Cancer

In the final overall survival analysis of the phase III CLEOPATRA trial, patients with HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the ESMO 2014...

Jul

Today In Oncology

Search Results

Your search for Javier Cort��s, MD,Javier Cort��s, MD matches 2 pages

No Benefit Shown With Afatinib in HER2-Positive Breast Cancer With Progressive Brain Metastases

ESMO 2014: CLEOPATRA Study Shows ‘Unprecedented’ Survival With Dual HER2 Blockade in Metastatic Breast Cancer

Zanidatamab Plus Chemotherapy in Advanced HER2-Positive Gastroesophageal Adenocarcinoma

Women Aged 65 Plus Still at Heightened Risk of HPV-Related Cervical Cancer

Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC

Optimizing the CAR to the Disease in B-Cell Malignancies

Study Supports Multi-Contaminant Water Treatment to Reduce Cancer Risk